Balanced news tone
News Sentiment
NXL sentiment intelligence
Nexalin Technology Inc. news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
Price is moving more forcefully than the current news tone suggests.
78/100 classification confidence.
directly relevant articles
high-authority source matches
+27.6% over one week, +6.9% over four weeks, trend inactive, and below fair value.
Nexalin Technology (NXL) Surges Over 11% as Shares Test Key Resistance Level - ATR Stop
Market Reaction
Price moving ahead of tone
Price is moving more forcefully than the current news tone suggests.
Sentiment Mix
Positive, neutral, negative
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
News Tape
Relevant headlines
Nexalin Technology (NXL) Surges Over 11% as Shares Test Key Resistance Level - ATR Stop
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 14 Jul 2026 18:47
- Source
- dars.gov.et
Reflecting On Medical Devices & Supplies - Specialty Stocks’ Q1 Earnings: Integer Holdings (NYSE:ITGR)
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 14 Jul 2026 18:07
- Source
- Market source
Nexalin Technology | ARS: Annual Report to Security Holders
This article confirms that Nexalin Technology has released its Annual Report to Security Holders (ARS). The content appears to be a direct document, likely containing detailed financial and operational information for shareholders.
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 11 Jul 2026 20:11
- Source
- Moomoo
Nexalin Technology (NXL) plans new 7M-share incentive pool and reverse split authority
Nexalin Technology (NXL) has announced plans for its virtual annual meeting on August 11, 2026, where stockholders will vote on several significant changes, including approving a new 2026 Equity Incentive Plan with an authorization for 7,000,000 shares. The company also seeks aut
- Tone
- Negative 37/100
- Event
- Market update
- Published
- 10 Jul 2026 20:09
- Source
- Stock Titan
Nexalin Technology (NXL) Q1 2026 Earnings: EPS Misses Estimates as Pre-Revenue Stage Continues
- Tone
- Negative 15/100
- Event
- Earnings
- Published
- 07 Jul 2026 23:30
- Source
- DonanımHaber
Enterprise value to revenue forward of Nexalin Technology, Inc. – NASDAQ:NXL
This article displays the "Enterprise value to revenue forward" metric for Nexalin Technology, Inc. (NASDAQ: NXL). It shows that this financial metric has a value and reports the change and percentage change for the specified period. The information is provided by TradingView, so
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 07 Jul 2026 08:12
- Source
- TradingView
Price to book forward of Nexalin Technology, Inc. – NASDAQ:NXL
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 05 Jul 2026 11:32
- Source
- TradingView
Price to earnings forward of Nexalin Technology, Inc. – NASDAQ:NXL
This article provides financial information for Nexalin Technology, Inc. (NASDAQ: NXL), specifically focusing on its Price to Earnings forward ratio. The page indicates that no trades were made when the market was closed and features a section for the company's financial data on
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 05 Jul 2026 11:39
- Source
- TradingView
Nexalin Technology (NXL) seeks shareholder votes for equity plan, reverse split
Nexalin Technology (NXL) is holding a virtual Annual Meeting of Stockholders on August 11, 2026, where shareholders will vote on several key proposals. These include the election of five directors, approval of the 2026 Equity Incentive Plan, authorization for a reverse stock spli
- Tone
- Neutral 50/100
- Event
- Regulatory and legal
- Published
- 29 Jun 2026 22:10
- Source
- Stock Titan
Form PRE 14A Nexalin Technology Inc For: 29 June By Investing.com
This article announces the filing of Form PRE 14A by Nexalin Technology Inc. for June 29th. The content primarily focuses on this regulatory filing, with ticker information for NXL provided.
- Tone
- Neutral 50/100
- Event
- Regulatory and legal
- Published
- 29 Jun 2026 21:39
- Source
- Investing.com South Africa
Nexalin Technology Secures US Patent for Deep-Brain Stimulation Targeting Insomnia
Nexalin Technology has secured a US patent for its non-invasive, frequency-based deep-brain neurostimulation method, specifically US Patent 12,629,519, which targets insomnia, anxiety, and depression. This patent safeguards the company's dynamic frequency stimulation method and i
- Tone
- Positive 90/100
- Event
- Market update
- Published
- 29 Jun 2026 19:10
- Source
- Sleep Review
Nexalin Technology, Inc. Actuals & Estimates (NASDAQ:NXL)
This article provides an overview of Nexalin Technology, Inc. (NASDAQ: NXL), including its financial actuals and estimates as well as analyst opinions. It details the company's stock performance, market capitalization, earnings, revenue, and future earnings report date. The artic
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 26 Jun 2026 19:39
- Source
- TradingView
NXL Forecast — Price Target — Prediction for 2027
This article provides a forecast and price target for Nexalin Technology, Inc. (NXL) stock for 2027, based on analyst opinions. It details the company's current stock price, past performance, earnings, revenue, market capitalization, and volatility, along with answers to frequent
- Tone
- Negative 26/100
- Event
- Earnings
- Published
- 25 Jun 2026 18:11
- Source
- TradingView
Nexalin Technology Announces that the Investigator of Its Brazilian Clinical Trial Received the Young Researcher Award at BRAIN 2026 for Research Evaluating the Company’s Proprietary DIFS™ Platform
Nexalin Technology announced that Dr. Victor Fontenelle Bastos de Lima, an investigator in their Brazilian clinical study, received the Young Researcher Award at BRAIN 2026 for his research. The award-winning study evaluated Nexalin's DIFS™ platform for insomnia symptoms in patie
- Tone
- Positive 71/100
- Event
- Market update
- Published
- 25 Jun 2026 07:09
- Source
- Market source
Nexalin Brazil sleep trial earns award at brain congress
Nexalin Technology announced that Dr. Victor Fontenelle Bastos de Lima, an investigator in its Brazilian clinical trial, received the Young Researcher Award at BRAIN 2026 for research on Nexalin's DIFS™ platform for anxiety and insomnia. The single-center study demonstrated signi
- Tone
- Positive 73/100
- Event
- Market update
- Published
- 23 Jun 2026 12:13
- Source
- Stock Titan
Nexalin Technology, Inc. Financial Disclosures & SEC Filings
This article provides access to Nexalin Technology, Inc.'s SEC filings and other financial documents, including quarterly and annual reports. It details financial performance, such as revenue and net loss figures, and highlights key operational updates, risks, and regulatory chal
- Tone
- Negative 20/100
- Event
- Earnings
- Published
- 21 Jun 2026 06:10
- Source
- TradingView
Nexalin Technology Inc (NXLIW) Technical Analysis: Support, Resistance, Indicators & Moving Averages
This article provides a technical analysis of Nexalin Technology Inc (NXLIW), focusing on various indicators and moving averages. It highlights that most indicators, including MACD and TRIX, alongside all moving averages (MA5 to MA200), signal a "Sell" for the stock. The article
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 19 Jun 2026 23:08
- Source
- TradingKey
Nexalin Technology Inc (NXL) Valuation: PE, PB & Fair Value Analysis
Nexalin Technology Inc (NXL) currently holds a valuation score of 7.68, placing it 140th out of 203 companies in the Healthcare Equipment & Supplies industry. Its P/E ratio is -0.80, which is detailed relative to its recent high and low. The article notes that relevant data for P
- Tone
- Negative 40/100
- Event
- Market update
- Published
- 19 Jun 2026 11:40
- Source
- TradingKey
Nexalin Technology Inc (NXL) Financial Health: Profitability & Balance Sheet Analysis
Nexalin Technology Inc (NXL) currently holds a financial score of 6.21, placing it 169th out of 203 in the Healthcare Equipment & Supplies industry. The company exhibits robust financial status despite low operating efficiency. Its latest quarterly revenue saw a 63.55% year-over-
- Tone
- Negative 39/100
- Event
- Earnings
- Published
- 19 Jun 2026 02:39
- Source
- TradingKey
Nexalin Technology Inc (NXL) Technical Analysis: Support, Resistance, Indicators & Moving Averages
This article provides a technical analysis of Nexalin Technology Inc (NXL), detailing its current price momentum, support and resistance levels, and various technical indicators. It notes that NXL is currently trading between a resistance level of $0.56 and a support level of $0.
- Tone
- Negative 32/100
- Event
- Market update
- Published
- 19 Jun 2026 02:39
- Source
- TradingKey
Nexalin Technology Inc (NXL) Institutional Confidence
Nexalin Technology Inc (NXL) has an institutional shareholding score of 3.00, placing it 132nd in the Healthcare Equipment & Supplies industry. The institutional shareholding proportion increased by 79.03% quarter-over-quarter to 6.94%. The largest institutional shareholder is Ja
- Tone
- Positive 61/100
- Event
- Market update
- Published
- 19 Jun 2026 01:39
- Source
- TradingKey
Nexalin Technology Inc (NXL) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
This article provides a detailed revenue breakdown for Nexalin Technology Inc (NXL), categorizing its revenue by business segments and regional sales. For the listed period, Device Sales and International Sales are the primary contributors. The data is presented with specific fig
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 18 Jun 2026 05:10
- Source
- TradingKey
Nexalin Technology Adopts Second Amended and Restated Bylaws Effective June 16, 2026
Nexalin Technology, Inc. has adopted new Second Amended and Restated Bylaws, effective June 16, 2026. These comprehensive updates revise procedures for shareholder meetings, director elections, board structure, and officer roles, aiming to streamline operations and align with cur
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 18 Jun 2026 02:09
- Source
- Minichart
Nexalin Technology Inc (NXLIW) Institutional Confidence
This article provides details on the institutional confidence score for Nexalin Technology Inc (NXLIW). It notes that the company has not yet disclosed relevant data regarding institutional shareholding and shareholder activity. The financial overview shows the stock price and ma
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 18 Jun 2026 02:09
- Source
- TradingKey
Nexalin Technology Inc (NXLIW) Earnings Forecast: Future EPS & Revenue Growth Estimates
This article provides an earnings forecast for Nexalin Technology Inc (NXLIW), indicating that relevant financial data for EPS, Revenue, and Net Profit has not yet been disclosed by the company. It notes that analyst ratings and target prices are for informational purposes only.
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 18 Jun 2026 01:09
- Source
- TradingKey
Nexalin Technology (NXL) overhauls bylaws, lowers quorum and adds exclusive forum rules
Nexalin Technology (NXL) has adopted Second Amended and Restated Bylaws, significantly altering its corporate governance framework. Key changes include updated advance notice procedures for stockholder nominations, a reduced quorum requirement for stockholder meetings from a majo
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 17 Jun 2026 21:00
- Source
- Stock Titan
Nexalin Technology Inc (NXL) Earnings Forecast: Future EPS & Revenue Growth Estimates
Nexalin Technology Inc (NXL) currently holds an earnings forecast score of 8.00, placing it 66th out of 203 in the Healthcare Equipment & Supplies industry. Analysts have set an average price target of $4.00 for NXL, uniformly across high and low forecasts. The company's expected
- Tone
- Positive 66/100
- Event
- Earnings
- Published
- 17 Jun 2026 11:08
- Source
- TradingKey
Nexalin Technology Announces Two Clinical Abstracts Accepted for Presentation at the 2026 NYC Neuromodulation Conference Highlighting Preliminary Clinical Results Across Anxiety, Depression, Insomnia and Quality of Life
Nexalin Technology announced that two clinical abstracts, based on data from an 8-week pilot trial, have been accepted for presentation at the 2026 NYC Neuromodulation Conference. These abstracts showcase the company's proprietary DIFS™ 15 mA 77.5 Hz treatment platform, demonstra
- Tone
- Positive 92/100
- Event
- Earnings
- Published
- 17 Jun 2026 10:09
- Source
- GlobeNewswire
Nexalin abstracts accepted at NYC neuromodulation conference By Investing.com
Nexalin Technology, Inc. announced that two clinical abstracts detailing positive results from an 8-week pilot clinical trial for its neurostimulation treatment platform have been accepted for presentation at the 2026 NYC Neuromodulation Conference. The study showed significant r
- Tone
- Positive 64/100
- Event
- Earnings
- Published
- 17 Jun 2026 07:41
- Source
- Investing.com South Africa
Nexalin Technology Inc (NXLIW) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
The article discusses the revenue breakdown of Nexalin Technology Inc (NXLIW), focusing on business segments, regional revenue, and profit contribution. It notes that relevant financial data has not yet been disclosed by the company, indicating a lack of detailed public informati
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 17 Jun 2026 00:41
- Source
- TradingKey